Clinical Value of lncRNA MEG3 in High-Grade Serous Ovarian Cancer.
MEG3
cancer biomarkers
lncRNAs
ovarian cancer cell lines
ovary
overall survival
personalized medicine
progression-free survival
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
14 Apr 2020
14 Apr 2020
Historique:
received:
17
03
2020
revised:
08
04
2020
accepted:
11
04
2020
entrez:
17
4
2020
pubmed:
17
4
2020
medline:
17
4
2020
Statut:
epublish
Résumé
Long non-coding RNAs (lncRNAs) are emerging as regulators in cancer development and progression, and aberrant lncRNA profiles have been reported in several cancers. Here, we evaluated the potential of using the maternally expressed gene 3 (MEG3) tissue level as a prognostic marker in high-grade serous ovarian cancer (HGSOC), the most common and deadliest gynecologic malignancy. To the aim of the study, we measured MEG3 transcript levels in 90 pre-treatment peritoneal biopsies. We also investigated MEG3 function in ovarian cancer biology. We found that high MEG3 expression was independently associated with better progression-free (
Identifiants
pubmed: 32295169
pii: cancers12040966
doi: 10.3390/cancers12040966
pmc: PMC7226118
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Oncotarget. 2015 Aug 7;6(22):18966-79
pubmed: 26136338
Int J Clin Exp Pathol. 2015 Sep 01;8(9):10953-63
pubmed: 26617813
Oncotarget. 2016 Jul 12;7(28):44719-44734
pubmed: 26992233
PLoS One. 2013 Sep 04;8(9):e72162
pubmed: 24023729
Eur J Cancer. 2016 May;59:22-33
pubmed: 26998845
J Hum Transcr. 2015 Jan 1;1(1):2-9
pubmed: 27335896
Br J Cancer. 2010 May 25;102(11):1555-77
pubmed: 20502460
Nat Med. 2015 Nov;21(11):1253-61
pubmed: 26540387
Crit Rev Oncol Hematol. 2014 Feb;89(2):207-16
pubmed: 24071502
Sci Rep. 2019 Apr 2;9(1):5515
pubmed: 30940866
Cancers (Basel). 2018 Nov 12;10(11):
pubmed: 30424539
Oncol Rep. 2014 Jul;32(1):277-85
pubmed: 24859196
Front Mol Neurosci. 2013 Nov 26;6:43
pubmed: 24324399
Cancer Discov. 2011 Oct;1(5):391-407
pubmed: 22096659
Cancer Chemother Pharmacol. 2017 Mar;79(3):479-487
pubmed: 28175963
J Cell Biochem. 2019 Oct;120(10):17709-17722
pubmed: 31161607
Med Sci Monit. 2019 Jun 24;25:4699-4704
pubmed: 31233485
Genome Biol. 2002 Jun 18;3(7):RESEARCH0034
pubmed: 12184808
J Clin Oncol. 2001 Oct 15;19(20):4054-7
pubmed: 11600607
Cancer Res. 2008 Jan 15;68(2):425-33
pubmed: 18199536
Nucleic Acids Res. 2017 Jul 3;45(W1):W98-W102
pubmed: 28407145
Histopathology. 2011 Jan;58(2):265-75
pubmed: 21323952
Control Clin Trials. 1996 Aug;17(4):343-6
pubmed: 8889347
Commun Biol. 2020 Feb 5;3(1):56
pubmed: 32024996
J Pathol. 2010 May;221(1):49-56
pubmed: 20229506
J Mol Endocrinol. 2012 Apr 02;48(3):R45-53
pubmed: 22393162
Genome Res. 2012 Sep;22(9):1775-89
pubmed: 22955988
Genome Biol. 2014 Jan 07;15(1):R6
pubmed: 24393600
Cancer Lett. 2017 Apr 10;391:12-19
pubmed: 28111137
Cancer Res. 2010 Jul 15;70(14):5891-900
pubmed: 20587520
Oncotarget. 2017 Aug 4;8(42):73282-73295
pubmed: 29069869
RNA. 2017 Jul;23(7):1080-1087
pubmed: 28386015
Carcinogenesis. 2006 Jul;27(7):1404-9
pubmed: 16400187
Noncoding RNA Res. 2018 Mar 31;3(3):108-117
pubmed: 30175284
Sci Rep. 2016 Dec 12;6:38983
pubmed: 27941916
Cancer Res. 2017 Aug 1;77(15):3965-3981
pubmed: 28701486
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Genome Biol. 2014 Dec 17;15(12):526
pubmed: 25608477
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
pubmed: 10655437
Mol Cancer. 2017 Jun 21;16(1):107
pubmed: 28637507
Gynecol Oncol. 2018 Mar;148(3):559-566
pubmed: 29310950
Inflamm Res. 2018 Dec;67(11-12):927-936
pubmed: 30310931
Cancer Biol Med. 2017 Feb;14(1):9-32
pubmed: 28443200
PLoS One. 2014 Sep 17;9(9):e103988
pubmed: 25230021
Cancers (Basel). 2019 Jun 25;11(6):
pubmed: 31242614
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Nutr. 2008 Jul;138(7):1360-4
pubmed: 18567761
Lab Invest. 2013 May;93(5):528-42
pubmed: 23459371
Nat Rev Mol Cell Biol. 2018 Sep;19(9):547-562
pubmed: 29858604